← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
CGTBiologicEpicentRx, Inc.Phase 2

Checkpoint Inhibitor, Immune (Checkpoint Inhibitor, Immune)

Solid Tumor, Adult; Cancer · Solid Tumor, Adult

#SolidTumorAdult#CGT#Phase2#인기#세포유전치료+5
효능 ORR 59%임상시험 60상태 RECRUITING
CGTBiologicMedigene AGPhase 2

Lymphodepletion (Lymphodepletion)

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
효능 0%임상시험 60상태 DISCONTINUED
ADCBiologicQilu Pharmaceutical Co., Ltd.Phase 2

QL1706 (QL1706)

TNBC, Triple Negative Breast Cancer · Recurrent Cervical Cancer

#RecurrentCervicalCancer#ADC#Phase2#인기#항체약물접합체+5
임상시험 60상태 RECRUITING
AntibodySun Yat-sen Universityvedotin combined with immun…Phase 3

Serplulimab (Serplulimab)

Colorectal Cancer; Liver Metastases · Solid Tumor Cancer

#SolidTumorCancer#Antibody#Phase3#인기#항체+5
임상시험 60상태 RECRUITING
CGTBiologicSabz BiomedicalsPhase 2

cytokine-induced killer cell (cytokine-induced killer cell)

Colon Cancer Stage IV · Solid Tumors

#SolidTumors#CGT#Phase2#인기#세포유전치료+5
임상시험 60상태 ACTIVE
ADCBiologicCanadian Cancer Trials Groupderuxtecan (T-DXd) showed a…Phase 2

darolutamide (darolutamide)

Prostate Cancer · Genitourinary Cancers

#GenitourinaryCancers#ADC#Phase2#인기#항체약물접합체+4
임상시험 60상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+4
효능 ORR 77.8%임상시험 60상태 RECRUITING
ADCBiologicGruppo Oncologico del Nord-OvestPhase 3

l-leucovorin (l-leucovorin)

Metastatic Colorectal Cancer · Gastric Cancer

#GastricCancer#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 36.6%임상시험 60상태 ACTIVE
CGTBiologicGamma Medica-IdeasPhase 2

tamoxifen citrate (tamoxifen citrate)

Male Breast Cancer; Stage II Breast Cancer · Breast Cancer

#BreastCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 13%임상시험 60상태 ACTIVE
ADCBiologicSWOG Cancer Research NetworksPhase 3

Afatinib Dimaleate (Afatinib Dimaleate)

Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 96%임상시험 59상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…releasePhase 2

Alpelisib (Alpelisib)

Breast Cancer; Gastrointestinal Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 43.3%임상시험 59상태 DISCONTINUED
ADCBiologicGenentech, Inc.Preclinical

Anti-angiogenic drug (Anti-angiogenic drug)

Gastric Cancer; Second-line Treatment · Gastric Cancer

#GastricCancer#ADC#Preclinical#인기#항체약물접합체+3
효능 ORR 96%임상시험 59상태 RECRUITING
AntibodyRegeneronDemonstratePhase 2

Cemiplimab + Fianlimab [Fixed Dose Combination (FDC, Cemiplimab + Fianlimab [Fixed Dose Combination, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)])

Ovarian Cancer; Fallopian Tube Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#인기#항체+5
효능 ORR 100%임상시험 59상태 RECRUITING
ADCBiologicMonika Joshi, MDviaPhase 3

Eribulin mesylate (Eribulin mesylate)

Metastatic Urothelial Cell Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 71.2%임상시험 59상태 RECRUITING
ADCBiologicSWOG Cancer Research NetworkDM1) and/or trastuzumab der…Phase 3

HER2-targeted Therapy (HER2-targeted Therapy)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 18.75%임상시험 59상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab and nivolumab)

Mesothelioma; Pancreatic Cancer · Uveal Melanoma, Metastatic

#UvealMelanomaMetastatic#Antibody#Phase2#인기#항체+5
효능 ORR 77.8%임상시험 59상태 RECRUITING
CGTBiologicImmunityBio, Inc.sPhase 2

Activated NK Cells (M-CENK, M-CENK (Activated NK Cells))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#인기#세포유전치료+4
임상시험 59상태 DISCONTINUED
CGTBiologicSPP Pharmaclon Ltd.Phase 2

Recombinant Interferon Alfa (Recombinant Interferon Alfa)

Colorectal Cancer; Kidney Cancer · Bladder Cancer

#BladderCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 32.4%임상시험 59상태 ACTIVE
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Trastuzumab emtansine, Trastuzumab emtansine (T-DM1))

Advanced Breast Cancer; Objective Response Rate · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 59상태 RECRUITING
ADCBiologicHoffmann-La RochePhase 2

Vismodegib (Vismodegib)

Cancer of Unknown Primary Site · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 88%임상시험 59상태 DISCONTINUED

7 / 75 페이지

← 이전다음 →